{"entity":{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","aka":[],"tldr":"Charles Blanke is a GI oncologist who chaired SWOG for a decade and led early imatinib trials in GIST.","summary":"Charles Blanke is Chief Medical Officer of the SWOG Cancer Research Network and Professor at Oregon Health & Science University. A gastrointestinal medical oncologist, he served as SWOG group chair from 2013 to 2025 before becoming chief medical officer. He led pivotal imatinib dose trials in gastrointestinal stromal tumour, reported in the Journal of Clinical Oncology as the phase III intergroup trial S0033 of imatinib at two dose levels in KIT-expressing GIST and the long-term results of a randomised phase II trial of standard versus higher-dose imatinib. His work spans sarcomas including GIST, colorectal cancer and clinical trial leadership.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blanke%20CD%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Charles%20D.%20Blanke"}],"tags":[],"related":[],"cancers":["sarcoma","colorectal"],"sections":[],"technologies":[],"targets":["kit"],"drugs":["imatinib"],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Medical Officer, SWOG Cancer Research Network; Professor, Oregon Health & Science University","institutionId":"swog","specialisms":["Gastrointestinal oncology","GIST","Clinical trial leadership"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blanke%20CD%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Charles%20D.%20Blanke"}],"papers":[{"title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","journal":"Journal of Clinical Oncology","year":2008,"url":"https://doi.org/10.1200/JCO.2007.13.4452","doi":"10.1200/JCO.2007.13.4452"},{"title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","journal":"Journal of Clinical Oncology","year":2008,"url":"https://doi.org/10.1200/JCO.2007.13.4403","doi":"10.1200/JCO.2007.13.4403"}]},"route":"/people/charles-blanke/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"}],"company":[{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/"}],"institution":[{"id":"ohsu-knight","kind":"institution","name":"OHSU Knight Cancer Institute","route":"/institutions/ohsu-knight/"}]}}